Navigation Links
Occlutech Wins Dutch Appeal Court Ruling Against AGA Medical
Date:10/22/2010

Occlutech Wins Dutch Appeal Court Ruling Against AGA Medical -- JENA, Germany, October 22, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Legal Issues Click to view news release full screen  

Occlutech Wins Dutch Appeal Court Ruling Against AGA Medical

 

JENA, Germany, October 22, 2010 /PRNewswire/ -- Occlutech GmbH, the leading European developer of minimally invasive implants for the treatment of structural heart disease, today announced receiving a favourable appeal court ruling from The Hague, The Netherlands in the on-going patent litigation with AGA Medical. A favourable first instance court ruling obtained by Occlutech had been appealed by AGA in 2008.

In the new ruling the appeal court of The Hague saw no reason to change the favourable first instance ruling. The Dutch appeal court decision is similar to the first instance as well as the appeal court rulings in the UK, the last one received in mid 2010. The rulings are subject to further appeal by AGA.

In Germany where Occlutech lost in the district and appeal courts of Dusseldorf in 2007 and 2008, causing a halt of sales and manufacturing activities in Germany, the German Supreme Court, (BGH), recently announced that it has allowed Occlutech's appeal. Occlutech expects a final decision in the first half of 2011 that, if in Occlutech's favour, will trigger substantial claims for re-payments and damages. Due to the litigation activity by AGA from 2006 and onwards, Occlutech has lost revenue, had products being destroyed and suffered the cost of litigation leading to potential damage claims in excess EUR 50 million.

In spite of the significant cost caused by the litigation and the related lack of sales in several markets, Occlutech's owners have funded work in maintaining and substantially strengthening Occlutech's own patent position and on a full pipe line of new technologies and products. In 2011 and 2012 Occlutech expects to launch additional occluders for indications such as PDA and VSD in addition to second generation ASD and PFO occluders. In addition, an innovative LAA occluder, a new generation of stent grafts and cardiac valve intervention technology are being developed.


'/>"/>
SOURCE Occlutech GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Leading Dutch Cancer Center Commences Treatments Using New TrueBeam from Varian Medical Systems
2. Dutch Public-Private Partnership Invests 28 Million Euro on Research Into Personalized Medicine
3. Maxygen, Inc. Announces Preliminary Results of Dutch Auction Tender Offer
4. Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer
5. Maxygen, Inc. Commences Dutch Auction Tender Offer to Repurchase 6,557,377 Shares of Common Stock
6. Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note
7. Par Pharmaceutical Announces Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010
8. Agendias MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
9. Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease
10. Mylan to Appeal Court Decision in Generic Paroxetine Hydrochloride CR Case
11. Statement of Ben Anderson, Esq., Regarding Denial of Wyeths En Banc Petition to Sixth Circuit Court of Appeals in Major Drug Regulation Pre-emption Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , April 29, 2016 ... H1 2016" market research report that provides an ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:4/29/2016)... PARIS , April 29, 2016 ... Jérôme Contamine, Directeur Financier ... la santé, publie ses résultats pour ... Financier du Groupe, Jérôme Contamine, commente ... Groupe et les perspectives pour le ...
(Date:4/29/2016)... 2016 Automation is one of ... to the growing demands for productivity in speed, accuracy, ... systems are already adept of a wide range of ... manual labor. Instrumentation continues to evolve, and is poised ... a few years ago. Originally used mostly by the ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... 2016 , ... Safety Week is an annual industry-wide initiative ... Industry Safety Initiative (CISI) and the Incident and Injury-Free (IIF) CEO Forum. ... industry to be leaders in safety. Statistics show that each year, more than ...
(Date:5/3/2016)... Garden City, NY (PRWEB) , ... May 04, 2016 , ... ... as a 2016-2017 inductee into its VIP Woman of the Year Circle. She ... leading networking organization exclusively for professional women, boasting more than 850,000 members and over ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... Journal, patients report dissatisfaction with numerous issues related to medical care in the ... billing, and poor bedside manner from hospital staff. Commenting on this article, the ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... its 2016 Champion Award to Charles D. Pulido, R.Ph., Co-Founder of NCPDP and ... M.S., Ph.D., Pharmacy Advisor and Health IT Specialist, Office of the National Coordinator ...
(Date:5/3/2016)... ... May 03, 2016 , ... Healing Cancer in ... patients and their families move toward recovery and is offered by creator and visionary ... Dr. Carol Francis Talk Radio show considering medical and healing modalities of the ...
Breaking Medicine News(10 mins):